prikaz prve stranice dokumenta Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
  Download
PDF 373.21 KB
Scientific paper - Original scientific paper
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Frontiers in Immunology, 11 (2021); 613954. https://doi.org/10.3389/fimmu.2020.613954
Tomaszewska, Agnieszka; Jagasia, Madan; Beohou, Eric; van der Werf, Steffie; Blaise, Didier; Kanfer, Edward; Milpied, Noel; Reményi, Péter; Ciceri, Fabio; Bourhis, Jean H.; Chevallier, Patrice; Solano, Carlos; Socié, Gerard; Bruno, Benedetto; Rambaldi, Alessandro; Castagna, Luca; Kröger, Nicolaus; Corradini, Paolo; Afanasyev, Boris; Ladetto, Marco; Niederwieser, Dietger; Scheid, Christof; Sengeloev, Henrik; Kroschinsky, Frank; Yakoub-Agha, Ibrahim; Schoemans, Helene; Koenecke, Christian; Penack, Olaf; Perić, Zinaida; Greinix, Hildegard; Duarte, Rafael F.; Basak, Grzegorz W. More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Tomaszewska, A., Jagasia, M., Beohou, E., van der Werf, S., Blaise, D., Kanfer, E. ... Basak, G. W. (2021). Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology, 11.. doi: 10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology, vol. 11, 2021. https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, Agnieszka, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, et al. "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies." Frontiers in Immunology 11 (2021). https://doi.org/10.3389/fimmu.2020.613954

Tomaszewska, A., et al. (2021) 'Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies', Frontiers in Immunology, 11. doi: 10.3389/fimmu.2020.613954

Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, and sur.. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. Frontiers in Immunology [Internet]. 2021 February [cited 2024 November 29];11. doi: 10.3389/fimmu.2020.613954

A. Tomaszewska, et al., "Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies", Frontiers in Immunology, vol. 11, February 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:878916. [Accessed: 29 November 2024]

Metadata
Title (english)Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
AuthorAgnieszka Tomaszewska
AuthorMadan Jagasia
AuthorEric Beohou
AuthorSteffie van der Werf
AuthorDidier Blaise
AuthorEdward Kanfer
AuthorNoel Milpied
AuthorPéter Reményi
AuthorFabio Ciceri
AuthorJean H. Bourhis
AuthorPatrice Chevallier
AuthorCarlos Solano
AuthorGerard Socié
AuthorBenedetto Bruno
AuthorAlessandro Rambaldi
AuthorLuca Castagna
AuthorNicolaus Kröger
AuthorPaolo Corradini
AuthorBoris Afanasyev
AuthorMarco Ladetto
AuthorDietger Niederwieser
AuthorChristof Scheid
AuthorHenrik Sengeloev
AuthorFrank Kroschinsky
AuthorIbrahim Yakoub-Agha
AuthorHelene Schoemans
AuthorChristian Koenecke
AuthorOlaf Penack
AuthorZinaida Perić
AuthorHildegard Greinix
AuthorRafael F. Duarte
AuthorGrzegorz W. Basak
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no randomized prospective data to validate this practice, although single center data and the CIBMTR analysis have shown promising results. We aimed at validation of these findings in a large registry study. We conducted a retrospective analysis using the EBMT registry of 3,803 adult patients with B-cell malignancies undergoing alloHCT (2001–2013) with either rituximab (R-RIC-9%) or non-rituximab (RIC-91%) reduced intensity regimens respectively. Median age and median follow up were 55 years (range 19.1–77.3) and 43.2 months (range 0.3–179.8), respectively. There was no difference in transplant outcomes (R-RIC vs RIC), including 1-year overall survival (69.9% vs 70.7%), 1-year disease-free survival (64.4% vs 62.2%), 1-year non-relapse mortality (21% vs 22%), and day-100 incidence of acute GVHD 2-4° (12% vs 12%). In summary, we found that addition of rituximab in RIC regimens for B-cell malignancies had no significant impact on major transplant outcome variables. Of note, data on chronic GVHD was not available, limiting the conclusions that can be drawn from the present study.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleFrontiers in Immunology
Numberingvol. 11, 613954
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2020.613954
URN:NBNurn:nbn:hr:105:878916
Publication2021-02
Document URLhttps://www.frontiersin.org/articles/10.3389/fimmu.2020.613954/full
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2021-06-29 08:27:34